{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "GTPase",
      "RAS",
      "cancer",
      "isoforms"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "27728979",
  "DateCompleted": {
    "Year": "2017",
    "Month": "02",
    "Day": "20"
  },
  "DateRevised": {
    "Year": "2017",
    "Month": "02",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "10",
        "Day": "12"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.2217/fon-2016-0363"
    ],
    "Journal": {
      "ISSN": "1744-8301",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "3",
        "PubDate": {
          "Year": "2017",
          "Month": "Feb"
        }
      },
      "Title": "Future oncology (London, England)",
      "ISOAbbreviation": "Future Oncol"
    },
    "ArticleTitle": "Rationale for RAS mutation-tailored therapies.",
    "Pagination": {
      "StartPage": "263",
      "EndPage": "271",
      "MedlinePgn": "263-271"
    },
    "Abstract": {
      "AbstractText": [
        "RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA."
          }
        ],
        "LastName": "Montalvo",
        "ForeName": "Steven K",
        "Initials": "SK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Departments of Biochemistry & Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA."
          }
        ],
        "LastName": "Li",
        "ForeName": "Lianbo",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Departments of Biochemistry & Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA."
          }
        ],
        "LastName": "Westover",
        "ForeName": "Kenneth D",
        "Initials": "KD"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Future Oncol",
    "NlmUniqueID": "101256629",
    "ISSNLinking": "1479-6694"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Protein Isoforms"
    },
    {
      "RegistryNumber": "EC 3.6.5.2",
      "NameOfSubstance": "ras Proteins"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Alleles"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Cell Transformation, Neoplastic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gene Expression Regulation, Neoplastic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genotype"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Targeted Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "diagnosis",
        "genetics",
        "mortality",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Patient Outcome Assessment"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Isoforms"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "ras Proteins"
    }
  ]
}